Pharma Journalist -

Vanda Pharmaceuticals has received Rare Pediatric Disease Designation from the US Food and Drug Administration for VCA-894A, an investigational antisense oligonucleotide therapy being…
Read More...

Vivani Medical has entered into a new agreement with Novo Nordisk that will allow the Danish drugmaker to evaluate Vivani’s NPM-139 semaglutide implant, a long-acting treatment…
Read More...

Biocytogen and Whitehawk Therapeutics have entered into a global collaboration to develop bispecific antibody-drug conjugates, or BsADCs, for cancer treatment. Under the agreement,…
Read More...

Novartis has agreed to acquire UK-based biotechnology company Myricx Bio for an upfront payment of $1.1 billion, with up to $400 million in additional milestone payments, as it looks to…
Read More...

AbbVie has received European Commission marketing authorization for TEPKINLY, or epcoritamab, in combination with lenalidomide and rituximab for adults with relapsed or refractory…
Read More...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash transaction valued at approximately $10 billion, expanding Vertex’s presence in rare endocrine…
Read More...

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to support the late-stage development and potential commercialization of ARCT-032, an…
Read More...

Lonza has acquired rights to Nona Biosciences’ transferrin receptor 1, or TfR1, blood-brain barrier technology, expanding its capabilities in central nervous system drug development and…
Read More...

Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...

AlzeCure Pharma AB has signed an out-licensing and collaboration agreement with Danish biotech company QuantumCell ApS for the global rights to its NeuroRestore platform, including its…
Read More...